公司資料
Alnylam Pharmaceuticals, Inc. 股價、新聞與催化劑
- 股票代碼:
- ALNY
- 交易所:
- NASDAQ
- 產業:
- Nucleic Acid Drugs
- 所在地:
- Cambridge, Massachusetts
股票表現
224.60 USD (-1.77%)
收盤價
最後更新: 2026年8月17日
38.2B USD
市值
股價為何變動
As of Aug 17, 2026, ALNY closed down 1.77% at $224.60. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Alnylam Pharmaceuticals is the pioneer of RNA interference therapeutics and one of the most important platform biotech companies in the market. Its approved medicines and pipeline programs focus on rare diseases and increasingly on more prevalent conditions.
所在地與產業分類
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Alnylam is a U.S.-based biotech with a growing global commercial footprint. It sits squarely in the innovation-heavy side of biotechnology.
商業模式特徵
The company combines product revenue, launch execution, and platform expansion with a deep RNAi pipeline. Investors watch adoption of approved medicines, label expansions, manufacturing scale, and the next wave of RNAi programs.
生技產業定位
Alnylam occupies a top-tier position in platform biotech because it has already proved RNAi can work commercially. Compared with earlier-stage names, it has more durability, but it still reacts to regulatory and pipeline milestones.
未來催化劑
- Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。